Cargando…
Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
BACKGROUND: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial h...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239022/ https://www.ncbi.nlm.nih.gov/pubmed/25412085 http://dx.doi.org/10.1371/journal.pone.0113086 |
_version_ | 1782345546877370368 |
---|---|
author | Naito, Akira Tanabe, Nobuhiro Jujo, Takayuki Shigeta, Ayako Sugiura, Toshihiko Sakao, Seiichiro Ishida, Keiichi Tatsumi, Koichiro |
author_facet | Naito, Akira Tanabe, Nobuhiro Jujo, Takayuki Shigeta, Ayako Sugiura, Toshihiko Sakao, Seiichiro Ishida, Keiichi Tatsumi, Koichiro |
author_sort | Naito, Akira |
collection | PubMed |
description | BACKGROUND: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers. METHODS: Plasma PTX3 and brain natriuretic peptide (BNP) levels were measured in 70 patients with CTEPH at their first diagnostic right heart catheterization (CTEPH group) and in 20 patients with clinically stable PTE more than three months after the acute episode (control group). The levels of plasma C-reactive protein (CRP) and heart-type fatty acid-binding protein (H-FABP) were also analyzed to compare the diagnostic ability of these biomarkers. RESULTS: The mean level of PTX3 (ng/mL) was significantly higher in the CTEPH group than in the control group (5.51±4.53 versus 2.01±0.96, respectively), and PTX3 levels had mild negative correlation with cardiac output. BNP levels were also higher in the CTEPH group and better correlated with pulmonary hemodynamics than PTX3. However, a receiver operating characteristic (ROC) curve showed PTX3 levels were better for detecting CTEPH, and could detect CTEPH patients with less severe pulmonary hemodynamics and low plasma BNP levels. There was no significant increase in CRP and H-FABP levels in the CTEPH patients. CONCLUSIONS: Plasma PTX3 level was the most sensitive biomarker of CTEPH. Although plasma PTX3 levels did not correlate with the severity of the pulmonary hemodynamics compared to BNP, high levels in clinically stable patients following PTE should prompt a further work-up for CTEPH, which may lead to an early diagnosis. |
format | Online Article Text |
id | pubmed-4239022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42390222014-11-26 Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism Naito, Akira Tanabe, Nobuhiro Jujo, Takayuki Shigeta, Ayako Sugiura, Toshihiko Sakao, Seiichiro Ishida, Keiichi Tatsumi, Koichiro PLoS One Research Article BACKGROUND: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers. METHODS: Plasma PTX3 and brain natriuretic peptide (BNP) levels were measured in 70 patients with CTEPH at their first diagnostic right heart catheterization (CTEPH group) and in 20 patients with clinically stable PTE more than three months after the acute episode (control group). The levels of plasma C-reactive protein (CRP) and heart-type fatty acid-binding protein (H-FABP) were also analyzed to compare the diagnostic ability of these biomarkers. RESULTS: The mean level of PTX3 (ng/mL) was significantly higher in the CTEPH group than in the control group (5.51±4.53 versus 2.01±0.96, respectively), and PTX3 levels had mild negative correlation with cardiac output. BNP levels were also higher in the CTEPH group and better correlated with pulmonary hemodynamics than PTX3. However, a receiver operating characteristic (ROC) curve showed PTX3 levels were better for detecting CTEPH, and could detect CTEPH patients with less severe pulmonary hemodynamics and low plasma BNP levels. There was no significant increase in CRP and H-FABP levels in the CTEPH patients. CONCLUSIONS: Plasma PTX3 level was the most sensitive biomarker of CTEPH. Although plasma PTX3 levels did not correlate with the severity of the pulmonary hemodynamics compared to BNP, high levels in clinically stable patients following PTE should prompt a further work-up for CTEPH, which may lead to an early diagnosis. Public Library of Science 2014-11-20 /pmc/articles/PMC4239022/ /pubmed/25412085 http://dx.doi.org/10.1371/journal.pone.0113086 Text en © 2014 Naito et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Naito, Akira Tanabe, Nobuhiro Jujo, Takayuki Shigeta, Ayako Sugiura, Toshihiko Sakao, Seiichiro Ishida, Keiichi Tatsumi, Koichiro Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism |
title | Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism |
title_full | Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism |
title_fullStr | Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism |
title_full_unstemmed | Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism |
title_short | Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism |
title_sort | pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239022/ https://www.ncbi.nlm.nih.gov/pubmed/25412085 http://dx.doi.org/10.1371/journal.pone.0113086 |
work_keys_str_mv | AT naitoakira pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT tanabenobuhiro pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT jujotakayuki pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT shigetaayako pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT sugiuratoshihiko pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT sakaoseiichiro pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT ishidakeiichi pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism AT tatsumikoichiro pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism |